IL17A and breast carcinoma: Apart from having a direct effect on the breast cancer cell leading to the activation of ERK1/2 and JNK signaling pathways through phosphorylation of tumor progression locus 2 (TPL2) (25), it seems that IL-17 can exert its protumor effect in various different ways.